CYCC : Analysis & Opinions

  1. Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst ...

    December 17, 2014
    In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
  2. Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx ...

    December 17, 2014
    It has been a relatively quiet week with the holiday season coming up though a few companies came out with important pipeline ...
Trading Center